Trenbolone hexahydrobenzylcarbonate is a synthetic 19-nortestosterone-derived anabolic-androgenic steroid carrying a hexahydrobenzylcarbonate ester that significantly extends its active half-life and release kinetics compared to shorter trenbolone esters.
Mechanism & Pharmacology of Trenbolone Hexahydrobenzylcarbonate
Trenbolone hexahydrobenzylcarbonate binds the androgen receptor with an affinity approximately three times greater than testosterone, making it one of the most potent androgen receptor agonists in practical use. This high-affinity binding translates into pronounced anabolic and androgenic activity, reflected by its anabolic ratio of approximately 500 and androgenic ratio of approximately 500 — both relative to a testosterone baseline of 100.
The hexahydrobenzylcarbonate ester is cleaved slowly by plasma esterases following intramuscular injection, releasing free trenbolone over an extended period. The elimination half-life of the active compound from this ester formulation is estimated at approximately 14 days, making it the longest-acting commercially produced trenbolone variant. This compares directly to trenbolone enanthate (approximately 7–10 days) and trenbolone acetate (approximately 2–3 days), placing hexahydrobenzylcarbonate firmly in the once-weekly or bi-weekly injection frequency bracket. The slow release profile means peak plasma concentrations are reached more gradually, which many experienced users find produces a smoother pharmacokinetic curve with less pronounced concentration spikes than shorter esters.
Trenbolone resists aromatisation by the enzyme aromatase, meaning it does not convert to oestrogen even at supraphysiological doses. It is, however, a potent progestin — trenbolone activates the progesterone receptor with meaningful affinity, a property inherited from its 19-nor structural class. This progestogenic activity is pharmacologically distinct from oestrogenic side-effect pathways and is an important consideration when designing supporting protocols.
At the cellular level, trenbolone hexahydrobenzylcarbonate promotes nitrogen retention, increases red blood cell production through erythropoietic stimulation, and markedly reduces glucocorticoid receptor signalling by competing with cortisol at shared receptor sites. The result is an amplified anabolic environment and attenuated catabolic signalling simultaneously. Bioavailability following intramuscular injection is effectively 100%, with no first-pass hepatic metabolism because administration bypasses the gastrointestinal tract entirely.
Application Context & User Groups
Trenbolone hexahydrobenzylcarbonate was originally developed and marketed as Parabolan by Négma Laboratories in France during the 1980s and 1990s, making it the only trenbolone ester ever approved for human pharmaceutical use — a distinction that separates it historically from acetate and enanthate variants, which remained exclusively veterinary or research-grade products in their original commercial forms.
Because of the long ester, trenbolone hexahydrobenzylcarbonate is best suited to cycle structures lasting at least 10–12 weeks, allowing plasma concentrations to build steadily and remain stable across the cycle's working phase. Shorter cycles do not provide adequate time for the ester to exert its full pharmacokinetic benefit. Typical injection frequencies used by experienced practitioners range from once every seven days to once every ten to fourteen days, depending on individual preference for peak-to-trough management.
The compound is principally selected by advanced users who have prior experience with shorter trenbolone esters and understand individual sensitivity to the active compound. First-time trenbolone users are generally directed toward the acetate ester, where dose titration and rapid clearance offer greater control. Users with established tolerance who prefer fewer injections and a more stable hormonal environment represent the primary user group for hexahydrobenzylcarbonate.
In the context of body composition goals, trenbolone hexahydrobenzylcarbonate is applied across both caloric surplus and caloric deficit phases. Its pronounced nutrient partitioning effect — where caloric intake is directed preferentially toward lean tissue over adipose storage — makes it genuinely versatile. The compound does not cause water retention due to its non-aromatising nature, which means physique changes attributable to it are typically lean and defined rather than volume-driven.
Stacking considerations typically pair trenbolone hexahydrobenzylcarbonate with a testosterone base to maintain androgen receptor saturation and manage suppression of endogenous testosterone production, which is severe with all trenbolone variants. The long ester lends itself well to pairing with other long-ester testosterone preparations, such as testosterone enanthate or testosterone cypionate, allowing injection schedules to be aligned efficiently.
Range & Selection by Concentration and Pack Size
The category currently lists 14 products from 14 distinct manufacturers, spanning concentration tiers of 75 mg/ml, 76 mg/ml, 76.5 mg/ml, 100 mg/ml, and 150 mg/ml. Both 10 ml vials and 10×1 ml ampule presentations are available, giving users practical flexibility based on dosing frequency and preferred administration format.
The 75–76.5 mg/ml tier is the closest to the original Parabolan pharmaceutical reference concentration of 76 mg/ml (equivalent to 50 mg per 0.66 ml ampule in the original Négma formulation). Products such as Hexos 75mg/ml 10ml Vial by Driada Medical and Parabolan 75mg/ml 10ml Vial by Hilma Biocare target users who prefer historically referenced dosing and may be working with conservative weekly volumes. This tier is particularly appropriate for those transitioning from pharmaceutical-reference-point research or for users managing total oil volume per injection site.
The 100 mg/ml tier is the most widely represented in this category and offers a practical balance between solution concentration and injectable volume. Parabolan 100mg/ml 10×1ml Ampoules by Balkan Pharmaceuticals and Parabol-100 100mg/ml 10×1ml Ampoules by BM Pharmaceuticals both present in ampule format, offering single-use sterility per injection — a preference for users prioritising contamination control. Parabolan 100 100mg/ml 10ml Vial by Dragon-Pharma and Trenboxyl Hexa 100 100mg/ml 10ml Vial by Kalpa Pharmaceuticals offer the same concentration in multi-use vial format, which suits users injecting more frequently or sharing the vial across a longer cycle timeline.
The 150 mg/ml tier represents the highest concentration available in this group and is suited to experienced users seeking to minimise total injection volume for equivalent doses. Higher-concentration solutions may carry greater solvent load, which some users find affects injection comfort; this is worth accounting for when selecting between tiers.
Ampule presentations are best suited to users who value single-dose sterility assurance, while vials offer practical convenience across extended cycles with lower per-unit waste.
Frequently Asked Questions
What is the half-life of trenbolone hexahydrobenzylcarbonate compared to other trenbolone esters?
Trenbolone hexahydrobenzylcarbonate carries an estimated elimination half-life of approximately 14 days, making it significantly longer-acting than trenbolone enanthate (7–10 days) and trenbolone acetate (2–3 days). This extended half-life supports once-weekly or bi-weekly injection schedules and produces a more stable plasma concentration curve throughout a cycle.
Why is trenbolone hexahydrobenzylcarbonate described as the only trenbolone ester approved for human use?
The original Parabolan, produced by Négma Laboratories in France, was the sole trenbolone preparation ever licensed as a human pharmaceutical product. It was withdrawn from the market in 1997. All subsequent trenbolone acetate and enanthate products were developed for veterinary or research applications. This historical distinction is why hexahydrobenzylcarbonate carries particular significance among researchers and enthusiasts familiar with the compound's origins.
Is trenbolone hexahydrobenzylcarbonate suitable for first-time trenbolone users?
Generally, trenbolone hexahydrobenzylcarbonate is not recommended as a first trenbolone experience. Its 14-day half-life means any adverse individual response takes considerably longer to clear than with the acetate ester. Most experienced practitioners suggest establishing trenbolone tolerance using the acetate form first, then transitioning to longer esters once individual response is well understood.
Best seller
